">
Thursday, 16 April 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 16 April 2026
News

Patient fury over pricing standoff

Posted 15 April 2026 AM

Breast Cancer Network Australia (BCNA) has accused Pfizer of "walking away from PBS pricing negotiations" for Tukysa and called for the “immediate establishment of a fully funded, open compassionate access program” for clinically eligible Australian women with metastatic breast cancer.

Despite the PBAC's positive recommendation for the brain-penetrating drug in November 2025, negotiations between Pfizer and the Department of Health have ground to a halt, according to BCNA.

To see the whole article, please login

Popular

Is this Big Pharma up for sale?
8 deaths overseas but no TGA alert
Much-loved CEO suddenly passes
Pfizer names local as Interim MD
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (13)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (1)

Other (9)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home